The execution of an investment term sheet is a defining milestone for any rapidly scaling digital health, medical device, or biopharmaceutical startup. While term sheets are largely non-binding, they establish the financial and legal blueprints for final binding transaction documents. For healthcare founders, a term sheet must address critical, sector-specific dynamics, including intellectual property warranties, milestone-based funding tranches tied to clinical trial approvals, and specialized board representation requirements.
Serving as the blueprint for angel or venture capital funding, a Term Sheet outlines key investment parameters such as pre-money valuation, investment amounts, liquidation preferences, and anti-dilution provisions. It establishes a mutual understanding of investment terms, enabling smooth drafting of definitive agreements while legally locking in essential terms like exclusivity, confidentiality, and due diligence timelines. It ensures that founders and investors are aligned on control, governance, and economics before incurring extensive legal fees.
Healthcare investors often structure their capital injections in tranches tied to specific regulatory milestones, such as successful bio-equivalence studies or IND clearances. Term sheet negotiations must ensure these milestones are realistic and clearly defined, preventing catastrophic cash shortfalls if a trial phase is delayed by regulatory backlogs.
Because healthcare ventures require multiple, highly dilutive funding rounds before achieving profitability, early founders must negotiate protective liquidation preferences. Ensuring these provisions are 'non-participating' and set at a standard 1x multiple protects the founding team's eventual payout from being entirely absorbed by late-stage institutional investors.
Establishes pre-money valuation, investment size, and post-money cap table layouts to prevent equity dilution surprises.
Defines the priority of payouts to investors in exit or liquidation events, establishing the financial risk-reward profile of the deal.
Legally binds the startup to stop seeking other investors during a set due diligence window, fostering trust and transaction momentum.
Establishes initial guidelines for future board composition, observer seats, and protective voting thresholds for investor approval.
The majority of a term sheet—such as valuation, investment size, board seats, and share rights—is non-binding and serves as a framework for negotiation. However, sections governing exclusivity, confidentiality, expenses, and governing law are explicitly drafted as legally binding commitments.
Liquidation preference determines the order of payouts during a liquidity event (like an acquisition or winding up). A 1x non-participating preference ensures investors get their original investment back before common shareholders receive any exit proceeds, protecting their downside risk.
The exclusivity or 'no-shop' clause typically lasts between 30 to 60 days. This legally restricts the founders from soliciting or negotiating funding deals with other investors while the current investor conducts detailed financial, legal, and technical due diligence.
Comprehensive solutions tailored perfectly to your industry.
Secures international brand protection in up to 132 countries through a centralized Madrid Protocol filing.
